2022
Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments
Jemaa S, Paulson J, Hutchings M, Kostakoglu L, Trotman J, Tracy S, de Crespigny A, Carano R, El-Galaly T, Nielsen T, Bengtsson T. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. Cancer Imaging 2022, 22: 39. PMID: 35962459, PMCID: PMC9373298, DOI: 10.1186/s40644-022-00476-0.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaProgression-free survivalOverall survivalFDG-PETUntreated diffuse large B-cell lymphomaHazard ratioHigh-risk DLBCL patientsCentral nervous system relapseLarge B-cell lymphomaMetabolic tumor volumeImaging-based risk factorsB-cell lymphomaEnhanced risk stratificationHigh-risk populationImaging metricsRisk increaseDLBCL patientsFDG-PET/CTSystemic relapseTumor volumeOrgan involvementPrognostic improvementRisk stratificationInvasive proceduresClinical dataPatient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study
Huang H, Datye A, Fan M, Knapp A, Nielsen T, Bottos A, Paulson J, Trask P, Efficace F. Patient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study. Cancer Medicine 2022, 11: 3312-3322. PMID: 35322932, PMCID: PMC9468432, DOI: 10.1002/cam4.4692.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaInternational Prognostic IndexProgression-free survivalLarge B-cell lymphomaB-cell lymphomaOverall survivalPrognostic valuePatient-reported outcomesPrognostic informationCox regression analysis of overall survivalClinical variablesAnalysis of overall survivalPhase III studyFifty-nine patientsCox regression analysisPatient risk stratificationPopulation of patientsEuropean Organization for Research and Treatment of Cancer Quality of LifeEuropean Organization for Research and TreatmentPlus chemotherapyIII studiesPrognostic indexTreatment of Cancer Quality of LifeGlobal health status/quality of lifeGlobal health status/qualityPrognostic mutational subtyping in de novo diffuse large B-cell lymphoma
Kim E, Jiang Y, Xu T, Bazeos A, Knapp A, Bolen C, Humphrey K, Nielsen T, Penuel E, Paulson J. Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma. BMC Cancer 2022, 22: 231. PMID: 35236331, PMCID: PMC8892802, DOI: 10.1186/s12885-022-09237-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicEnhancer of Zeste Homolog 2 ProteinExome SequencingFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedMutationPrognosisProto-Oncogene Proteins c-bcl-2RNA-SeqSulfonamidesTreatment OutcomeConceptsSequence dataWhole-exome sequencing dataExome-sequencing dataTargeted sequencing platformsExome sequencing dataTargeted sequencing dataBackgroundDiffuse large B-cell lymphomaLarge B-cell lymphomaSequencing platformsRNA-seqDe novo DLBCLImproved overall survivalTarget sequenceB-cell lymphomaVenetoclax therapyMutation subtypesPrognostic subsetsMutationsOverall survivalMolecular subsetsSubset distributionMutation groupSurvival outcomesMutation profilesClinical associations
2019
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study
Bolen C, Klanova M, Trneny M, Sehn L, He J, Tong J, Paulson J, Kim E, Vitolo U, Di Rocco A, Fingerle-Rowson G, Nielsen T, Lenz G, Oestergaard M. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. Haematologica 2019, 105: 2298-2307. PMID: 33054054, PMCID: PMC7556630, DOI: 10.3324/haematol.2019.227892.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaPrognostic impact of somatic mutationsCell-of-origin subtypesBCL2 alterationsCell of originPrognostic impactImpact of somatic mutationsMolecular heterogeneity of diffuse large B-cell lymphomaGerminal center B-cell-like diffuse large B-cell lymphomaHeterogeneity of diffuse large B-cell lymphomaTargeted DNA next-generation sequencingAssociated with shorter progression-free survivalShorter progression-free survivalSomatic mutationsDNA next-generation sequencingParaffin-embedded tissue biopsiesProgression-free survivalMultivariate Cox regressionBCL2 translocationsUntreated patientsPotential treatment targetPrognostic differencesPrognostic effect
2018
Cancer subtype identification using somatic mutation data
Kuijjer M, Paulson J, Salzman P, Ding W, Quackenbush J. Cancer subtype identification using somatic mutation data. British Journal Of Cancer 2018, 118: 1492-1501. PMID: 29765148, PMCID: PMC5988673, DOI: 10.1038/s41416-018-0109-7.Peer-Reviewed Original ResearchConceptsSomatic mutation dataAssociated with mutationsNext-generation sequencing technologiesMutation dataBiological pathwaysSets of mutationsSignal transduction pathwaysCancer typesPan-cancer subtypesSequencing technologiesPhenotypic dataCancer Genome AtlasCancer subtype identificationTransduction pathwaysMutational driversSomatic mutationsSubgroup of patientsTargeted treatment optionsMutationsMutation patternsGenome AtlasClassification of patientsMutation profilesPrimary tumorPrognostic subtypes